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Abstract
Background and Aims: Individuals with Lynch syndrome have a high lifetime risk of developing colorectal tumors. In this
prospective cohort study of individuals with Lynch syndrome, we examined associations between use of dietary
supplements and occurrence of colorectal adenomas.
Materials and Methods: Using data of 470 individuals with Lynch syndrome in a prospective cohort study, associations
between dietary supplement use and colorectal adenoma risk were evaluated by calculating hazard ratios (HR) and 95%
confidence intervals (CI) using cox regression models adjusted for age, sex, and number of colonoscopies during person
time. Robust sandwich covariance estimation was used to account for dependency within families.
Results: Of the 470 mismatch repair gene mutation carriers, 122 (26.0%) developed a colorectal adenoma during an overall
median person time of 39.1 months. 40% of the study population used a dietary supplement. Use of any dietary supplement
was not statistically significantly associated with colorectal adenoma risk (HR= 1.18; 95%CI 0.80–1.73). Multivitamin
supplement use (HR = 1.15; 95%CI 0.72–1.84), vitamin C supplement use (HR = 1.57; 95%CI 0.93–2.63), calcium supplement
use (HR= 0.69; 95%CI 0.25–1.92), and supplements containing fish oil (HR = 1.60; 95%CI 0.79–3.23) were also not associated
with occurrence of colorectal adenomas.
Conclusion: This prospective cohort study does not show inverse associations between dietary supplement use and
occurrence of colorectal adenomas among individuals with Lynch syndrome. Further research is warranted to determine
whether or not dietary supplement use is associated to colorectal adenoma and colorectal cancer risk in MMR gene
mutation carriers.
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Introduction
Individuals with Lynch syndrome have pathogenic germline
mutations in genes involved in DNA mismatch repair (MMR), i.e.
MLH1, MSH2, MSH6, PMS2, [1–5] or in the EPCAM gene.
[6,7] Approximately 3% of all colorectal cancers are induced by
Lynch syndrome. [8,9] The adenoma-carcinoma sequence seems
to be accelerated in MMR gene mutation carriers, [10] and
carriers have a 25–70% risk of developing colorectal cancer up to
age 70, at a relatively young age, [2–5,11] compared to 2–5% in
the general Western population. [12,13]
Removal of colorectal adenomas lowers risk of colorectal
carcinomas in individuals with Lynch syndrome. [14,15] There-
fore, those persons are generally advised to follow strict periodic
endoscopic surveillance to detect colorectal adenomas. [15,16]
Considering the high lifetime risk of developing adenomas and
carcinomas in MMR gene mutation carriers, [2–5] it is very
relevant to study whether modifiable lifestyle factors, including
dietary supplement use, can affect this risk. As shown in previous
studies from our group, excess body weight, [17] smoking, [18]
and a dietary pattern high in snack foods [19] were associated with
an increased risk of colorectal adenomas in persons with Lynch
syndrome. Retrospective case-control studies in Lynch syndrome
suspected-families showed that increased fruit consumption and
dietary fibre intake possibly decreased the risk of colorectal
tumors. [20]
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Although a healthy diet provides a sufficient amount of vitamins
and minerals, many individuals take vitamin and mineral
supplements regularly, hoping to further improve their health
and to prevent acute or chronic illnesses and serious diseases, such
as cancer. [21,22] Dietary supplement use and colorectal adenoma
risk have been extensively investigated in the general population.
No convincing evidence for an association between multivitamin
supplement use, [23] folic acid supplement use, [24] and
antioxidant supplement use and adenoma occurrence was found,
[25,26] whereas calcium supplement use might contribute to a
lower risk of colorectal adenomas. [27] MMR gene mutation
carriers might have a higher use of dietary supplements compared
to the general Dutch population based on their health status and
risk. [28] Up until now, as far as we know, no studies on dietary
supplement use and colorectal adenomas among individuals with
Lynch syndrome were conducted.
The objective of this study was to prospectively examine the
association between the most frequently used dietary supplements
and colorectal adenoma development in a cohort study of
individuals with Lynch syndrome.
Materials and Methods
Ethics Statement
The Medical Ethics Committee of the Radboud University
Nijmegen Medical Centre approved the study. All participants
gave written informed consent.
Study population
Individuals with Lynch syndrome participated in the GEO-
Lynch prospective cohort study which was described earlier. [17]
Briefly, carriers of a germline mutation in at least one of the
mismatch repair genes were identified via linkage to a hereditary
tumor registration of the Netherlands Foundation for the
Detection of Hereditary Tumors in Leiden, the Radboud
University Nijmegen Medical Center in Nijmegen, and the
University Medical Center Groningen in Groningen, the Nether-
lands. Participants had to be between 18 and 80 years of age,
Dutch-speaking, white, and mentally competent to participate in
this study to be eligible for the study. Terminally ill patients, and
those with familial adenomatous polyposis, inflammatory bowel
diseases, a complete proctocolectomy or colostomy were excluded.
With approval of their medical specialist, a total of 713
mutation carriers were invited to participate in the study between
July 2006 and July 2008. Six hundred ninety-five out of 713 people
could be contacted of whom nine were ineligible. Of these, 73%
(499 of 686) agreed to participate. We were unable to retrieve
medical and personal information from 29 participants. Therefore,
a total of 470 participants from at least 161 families were included
in this study.
Exposure assessment
At recruitment, dietary supplement use was collected using a
self-administered questionnaire. Information on dietary supple-
ment use included frequency of intake (no intake in the previous
month, once a month, 2–3 days a month, once a week, 2–3 days a
week, 4–5 days a week, 6–7 days a week), amount of intake (1, 2, 3,
4, or $5 tablets, capsules or droplets), and brand name of
multivitamins, vitamin C, B-vitamins, folic acid, vitamin D
(including vitamin A), vitamin E, calcium, iron, and fish oil
supplements. In addition, participants could indicate whether they
used other supplements that were not covered by the question-
naire. In this study, users of dietary supplements were defined as
those taking any dietary supplement during the last month. When
patients took no dietary supplements at all during the last month,
they were considered nonusers. Habitual dietary intake was
collected using a 183-item self-administered and validated food
frequency questionnaire. [29,30] General lifestyle information was
collected with a lifestyle questionnaire containing questions about
age, sex, weight, height, smoking habits, medication use, physical
activity,[31] family history of colorectal cancer, and medical
history.
Outcome data
Medical information, including information about medical
history and colorectal adenomas and carcinomas, was obtained
by reviewing medical records regularly from all subjects via the
participating centers until information was complete. From every
participant, information about previously performed colonosco-
pies, colorectal surgery, cancer, and adenomatous polyps was
gathered before recruitment and during follow up until December
31, 2010. We ascertained detailed information from pathology
reports about location, size, and histology for all documented
colorectal adenomas that occurred during follow up.
Data analysis
The outcome of our analysis was the time to diagnosis of the
first pathology-confirmed colorectal adenoma. Descriptive statis-
tics were used to describe the demographic characteristics, and
characteristics on lifestyle, medical status, dietary supplement use
and dietary intake of all 470 MMR gene mutation carriers and
from those who were diagnosed with a colorectal adenoma during
follow up. In addition, general characteristics were computed for
dietary supplement users versus nonusers. Differences in baseline
characteristics between users and non-users were tested by the
Mann-Whitney U test (continuous variables) or the x2 test
(categorical variables).
Cox proportional hazards regression was used to investigate
associations of dietary supplement use and colorectal adenoma
occurrence. Hazard ratios (HR) with 95% confidence intervals
(95% CI) were reported, and robust sandwich covariance
estimation was used to account for dependency of observations
within families. The Cox proportional hazard models were tested
for and met the assumption of proportionality by visually
inspecting whether the distance between the log(-log) survival
curves was approximately constant. Person time started at the date
of the most recent colonoscopy before assessment of dietary
supplement use and ended at the date of colonoscopy of the first
diagnosed colorectal adenoma during follow up. Participants
without a colorectal adenoma diagnosis or without a detectable
colorectal adenoma were censored at the date of their last known
colonoscopy during follow up.
The following covariates were evaluated as potentially con-
founding variables: age (continuous), sex, educational level
(categorical: high vs lower educated), number of colonoscopies
during person time (continuous), history of colorectal adenomas
(yes/no), history of carcinomas (yes/no), physical activity level
(categorical: high vs lower physically active), smoking status
(current, former, never), body mass index (continuous), regular
use of NSAIDs (,1 times/week, $1 times/week), alcohol intake
(g/d), total energy intake (kJ/d), total vegetables intake (g/d), total
fruit intake (g/d), and total red meat intake (g/d). In the basic
model, we adjusted for age and sex. Covariates were considered as
confounders if they correlated with any use of dietary supplements
and colorectal tumor risk, and if they changed the hazard ratio by
$10% using forward selection. The maximally adjusted model
included age, sex, and number of colonoscopies during person
time.
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Stratified analyses for the association of dietary supplement use
and colorectal adenoma risk were conducted for MMR carriers
with a history of colorectal neoplasms before study entry
(recurrence), and for those without (first occurrence). To assess
possible effect measure modification of associations between
dietary supplement use and colorectal adenoma risk, we stratified
our analysis for smoking status (never, former, current) and total
fruit and vegetables intake (in quartiles: ,179, 179–283, 283–387,
$387 g/day). Nonusers, who never smoked, were defined as
reference group to estimate HRs stratified for smoking status. In
addition, nonusers who had a relatively low intake of fruit and
vegetables of ,179 g/day, were defined as reference group to
evaluate HRs stratified for total fruit and vegetables intake. To test
for multiplicative interaction we used a log likelihood ratio test,
comparing models for nonusers and users by smoking status and
by strata of total fruit and vegetables intake.
A sensitivity analysis was performed for the association between
any use and use of specific types of dietary supplements and
Table 1. General characteristics of the mismatch repair gene mutation carriers in the GEOLynch prospective cohort study.
Total population
Colorectal adenoma
cases
(n =470) (n =122)
Person time [months, median (P25–P75)] 39.1 (25.1–49.8) 27.8 (22.4–47.3)
Demographic Age at study entry [years, median (P25–P75)] 50.2 (40.8–58.6) 53.0 (45.7–60.2)
characteristics Women [n (%)] 281 (59.8) 68 (56.0)
High education [n (%)] a 161 (34.6) 29 (24.0)
Lifestyle BMI [kg/m2, median (P25–P75)] 24.5 (22.5–26.9) 25.1 (23.4–27.1)
characteristics Current smokers [n (%)] 85 (18.1) 36 (29.5)
NSAID use [$1x/week, n (%)] 42 (9.1) 10 (8.2)
Physical activity [high; n (%)] b 154 (33.4) 41 (34.5)
Medical MMR gene mutation [n (%)] MLH1 178 (37.9) 49 (40.2)
characteristics MSH2 192 (40.9) 55 (45.1)
MSH6 95 (20.2) 17 (13.9)
PMS2 3 (0.6) 1 (0.8)
History of cancer [n (%)] CRC c 121 (25.7) 31 (25.4)
Other cancer 82 (17.5) 26 (21.3)
History of colorectal neoplasms [n (%)] d 232 (49.4) 73 (59.8)
No. of colonoscopies during person time [n (%)] 1 179 (38.1) 70 (57.4)
2 193 (41.1) 39 (32.0)
$3 95 (20.2) 10 (8.2)
Dietary Any [n (%)] 188 (40.0) 54 (44.3)
supplement use e Multivitamins [n (%)] 121 (25.7) 37 (30.3)
Vitamin C [n (%)] 61 (13.0) 17 (13.9)
Vitamin B complex [n (%)] 8 (1.7) 1 (0.8)
Vitamin E [n (%)] 9 (1.9) 1 (0.8)
Vitamin D [n (%)] 6 (1.3) 1 (0.8)
Folic acid [n (%)] 9 (1.9) 1 (0.8)
Calcium [n (%)] 22 (4.7) 6 (4.9)
Iron [n (%)] 3 (0.6) 0
Fish oil [n (%)] 32 (6.8) 13 (10.7)
Other [n (%)] f 58 (12.3) 20 (16.4)
Dietary intake Total energy [kJ/day, mean6SD] 905562798 871162702
Vegetables intake [g/day, median (P25–P75)] 123 (76–176) 124 (61–173)
Fruit intake [g/day, median (P25–P75)] 157 (75–234) 136 (44–234)
Red meat intake [(g/day, median (P25–P75)] 46 (30–64) 50 (30–67)
Alcohol intake [g/day, median (P25–P75)] 7.2 (1.5–16.8) 9.4 (3.2–21.8)
a College or university degree
b Highest tertile of the physical activity score
c CRC= colorectal cancer
d History of colorectal adenoma and/or carcinoma
e Use of any dietary supplement during the last month
f E.g. glucosamine/chondroitin supplements, and garlic pills
doi:10.1371/journal.pone.0066819.t001
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colorectal adenoma risk, in which person time started at the time
of assessment of dietary supplement use. P,0.05 was considered
statistically significant. All analyses were performed using SAS
version 9.2 (SAS Institute Inc., Cary, NC).
Results
In this cohort of MMR gene mutation carriers, 122 (26.0%) of
470 subjects developed a colorectal adenoma during an overall
median person time of 39.1 months (table 1). The total person time
was 18,449 person months. About 44% of the colorectal adenoma
Table 2. General characteristics of the mismatch repair gene mutation carriers stratified by dietary supplement use in the
GEOLynch prospective cohort study.
Dietary supplement users
Users a Nonusers b p-value h
(n=188) (n =282)
Person time [months, median (P25–P75)] 36.6 (24.4–49.4) 41.8 (26.0–50.2) 0.17
Demographic Age at study entry [years, median (P25–P75)] 51.7 (42.1–58.6) 48.9 (39.6–58.6) 0.17
characteristics Women [n (%)] 128 (68.1) 153 (54.3) ,0.01
High education [n (%)] c 70 (37.4) 91 (32.7) 0.59
Lifestyle BMI [kg/m2, median (P25–P75)] 24.1 (21.9–26.3) 24.7 (22.9–27.5) 0.23
characteristics Current smokers [n (%)] 31 (16.5) 54 (19.2) 0.15
NSAID use [$1x/week, n (%)] 17 (9.2) 25 (9.1) 0.97
Physical activity [high; n (%)] d 63 (34.2) 91 (32.9) 0.76
Medical MMR gene mutation [n (%)] MLH1 76 (40.4) 102 (36.2) 0.27
characteristics MSH2 66 (35.1) 126 (44.7)
MSH6 43 (22.9) 52 (18.4)
PMS2 2 (1.1) 1 (0.4)
Colorectal adenoma cases during follow up [n (%)] 54 (28.7) 68 (24.1) 0.28
History of cancer [n (%)] CRC e 50 (26.6) 71 (25.2) 0.73
Other cancer 41 (21.8) 41 (14.5) 0.04
History of colorectal neoplasms [n (%)] f 99 (52.7) 133 (47.2) 0.31
No. of colonoscopies during person time [n (%)] 1 69 (36.7) 110 (39.0) 0.83
2 80 (42.6) 113 (40.1)
$3 37 (19.7) 58 (20.6)
Dietary Multivitamins [n (%)] 121 (64.4) -
supplement Vitamin C [n (%)] 61 (32.5) -
use a Vitamin B complex [n (%)] 8 (4.3) -
Vitamin E [n (%)] 9 (4.8) -
Vitamin D [n (%)] 6 (3.2) -
Folic acid [n (%)] 9 (4.8) -
Calcium [n (%)] 22 (11.7) -
Iron [n (%)] 3 (1.6) -
Fish oil [n (%)] 32 (17.0) -
Other [n (%)] g 58 (30.9) -
Dietary intake Total energy intake [kJ/day, mean6SD] 887162647 917962893 0.36
Vegetables intake [g/day, median (P25–P75)] 123 (81–177) 125 (73–175) 0.61
Fruit intake [g/day, median (P25–P75)] 167 (79–235) 130 (53–233) 0.11
Red meat intake [(g/day, median (P25–P75)] 46 (27–63) 46 (34–64) 0.38
Alcohol intake [g/day, median (P25–P75)] 6.7 (1.6–16.3) 7.4 (1.5–17.1) 0.69
a Use of any dietary supplement during the last month
b No use of dietary supplement during the last month
c College or university degree
d Highest tertile of the physical activity score [31]
e CRC= colorectal cancer
f History of colorectal adenoma and/or carcinoma
g E.g. glucosamine/chondroitin supplements, and garlic pills
h Calculated using Mann-Whitney U test for continuous variables or the x2 test for categorical variables
doi:10.1371/journal.pone.0066819.t002
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cases used a dietary supplement versus 40% in the total cohort.
Colorectal adenoma cases were slightly older and lower educated
compared to the total cohort. In addition, more persons smoked
and alcohol intake was higher in colorectal adenoma cases
compared to the total cohort.
Of the dietary supplement users, 28.7% developed a colorectal
adenoma during the follow up period (table 2); this was 24.1% in
nonusers. Compared to nonusers, dietary supplement users were
slightly older, were more often women, were more often higher
educated, smoked less often, had more often a history of cancer or
colorectal tumors, and consumed more fruit.
Use of any dietary supplement was not statistically significantly
associated with colorectal adenoma risk (HR=1.18; 95% CI 0.80–
1.73) after adjustments for age, sex, and number of colonoscopies
during person time (table 3). In addition, no associations were
found between colorectal adenomas and multivitamin supplement
use (HR=1.15; 95% CI 0.72–1.84), vitamin C supplement use
(HR=1.57; 95% CI 0.93–2.63), calcium supplement use
(HR=0.69; 95% CI 0.25–1.92), and supplements containing fish
oil (HR=1.60; 95% CI 0.79–3.23).
In this study population, 73 of the 232 MMR carriers with a
history of colorectal neoplasms before study entry developed a
colorectal adenoma during follow up, of which 36 were dietary
supplement user. In MMR carriers without a history of colorectal
neoplasms (n= 238), 49 subjects developed a colorectal adenoma
of which 18 subjects used a dietary supplement. Among MMR
carriers with a history of colorectal neoplasms, dietary supplement
use was not statistically significantly associated with colorectal
adenoma risk (HR=0.87; 95% CI 0.44–1.75). However, a
borderline statistically significantly increased risk was observed
for dietary supplement use and colorectal adenoma risk among
those without a history of colorectal neoplasms (HR=1.60; 95%
CI 0.98–2.60).
Table 4 shows that there is no effect measure modification with
smoking status (p for multiplicative interaction: 0.41) and total fruit
and vegetables intake (p for multiplicative interaction: 0.39) in the
association of dietary supplement use and colorectal tumor risk. In
a sensitivity analysis, in which person time started at the time of
assessment of dietary supplement use, no differences in associa-
tions were observed for any use or use of specific types of dietary
Table 3. Association of dietary supplement use and colorectal adenoma risk in the GEOLynch prospective cohort study of MMR
gene mutation carriers.
Dietary supplement use No use
a Use b
HR HR (95% CI)
Any dietary supplement No. of cases/non-cases 68/214 54/134
Person time (months, median) 41.8 36.6
HR, adjusted for age & sex 1.0 1.21 (0.85–1.72)
HR, adjusted for age, sex, and number of
colonoscopies during person time
1.0 1.18 (0.80–1.73)
Multivitamins No. of cases/non-cases 85/264 37/84
Person time (months, median) 39.6 37.5
HR, adjusted for age & sex 1.0 1.38 (0.93–2.07)
HR, adjusted for age, sex, and number of
colonoscopies during person time
1.0 1.15 (0.72–1.84)
Vitamin C No. of cases/non-cases 105/304 17/44
Person time (months, median) 39.9 34.5
HR, adjusted for age & sex 1.0 1.36 (0.80–2.31)
HR, adjusted for age, sex, and number of
colonoscopies during person time
1.0 1.57 (0.93–2.63)
Calcium No. of cases/non-cases 116/332 6/16
Person time (months, median) 39.2 36.9
HR, adjusted for age & sex 1.0 0.68 (0.24–1.93)
HR, adjusted for age, sex, and number of
colonoscopies during person time
1.0 0.69 (0.25–1.92)
Fish oil No. of cases/non-cases 109/329 13/19
Person time (months, median) 39.2 37.1
HR, adjusted for age & sex 1.0 1.74 (1.00–3.01)
HR, adjusted for age, sex, and number of
colonoscopies during person time
1.0 1.60 (0.79–3.23)
a No use of dietary supplements during the last month
b Use of any dietary supplement during the last month
doi:10.1371/journal.pone.0066819.t003
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supplements and colorectal adenoma risk. However, a borderline
statically significantly increased risk of colorectal adenomas was
observed for persons who took supplements containing fish oil
(HR=1.78; 95% CI 0.92–3.45).
Discussion
The present study did not observe a statistically significant
association between use of any dietary supplement and colorectal
adenoma risk among individuals with Lynch syndrome. No
marked associations were found for multivitamin supplement
use, vitamin C supplement use, calcium supplement use, and use
of supplements containing fish oil and colorectal adenoma risk
either.
To our best knowledge, this is the first prospective cohort study
that examined the association of dietary supplement use and
development of colorectal adenomas in individuals with Lynch
syndrome. The association between dietary supplement use and
sporadic colorectal adenoma risk in the general population has
been investigated in many epidemiological studies. [23–27] Our
findings for dietary supplement use and colorectal adenoma risk in
individuals with Lynch syndrome were largely consistent with
findings in the general population. Calcium supplement use might
contribute to a lower risk of colorectal adenomas in the general
population. [27] However, no evidence of association was found
for calcium supplement use and colorectal adenoma risk in this
Lynch syndrome population. A randomized, double-blind, place-
bo-controlled trial with calcium supplements, conducted in 30
first-degree relatives of Lynch syndrome patients, showed a small
but nonstatistically significant reduction in epithelial cell prolifer-
ation in biopsies of the rectum, and no effect in the sigmoid and
descending colon compared with placebo after 12 weeks of
intervention. [32] Those results also do not suggest that the use of
calcium supplements may help to lower the increased risk of
colorectal adenoma occurrence among mismatch repair gene
carriers.
No significant association was shown for fish oil supplements
and colorectal adenoma risk, when person time started at the date
of the most recent colonoscopy before assessment of dietary
supplement use. However, according to sensitivity analyses when
person time started at the time of assessment of dietary supplement
use, a borderline statistically significantly increased risk for
colorectal adenomas was observed for Lynch syndrome patients
who took fish oil supplements. Our findings should be interpreted
with caution, as our hazard ratios appear to be unstable, probably
due to the low number of fish oil supplement users in our study.
Moreover, the possible detrimental role of supplements containing
fish oil on colorectal tumor risk in Lynch syndrome patients
contrasts with findings in the general population: fish oil, and then
particularly n-3 PUFA from fish oil, are thought to play a
Table 4. Association of any dietary supplement use and colorectal adenoma risk stratified for smoking status and total fruit and
vegetables intake in the GEOLynch prospective cohort study of MMR gene mutation carriers.
Smoking status
Dietary supplement use Never Former Current
No use a
No. of cases/non-cases 17/99 28/83 23/31
Person time (months, median) 46.0 44.9 31.0
HR (95% CI) adjusted for age, sex, and number of
colonoscopies during person time
1.0 1.54 (0.84–2.84) 2.54 (1.42–4.54)
Use b
No. of cases/non-cases 8/56 33/60 13/18
Person time (months, median) 37.2 35.9 39.1
HR (95% CI) adjusted for age, sex, and number of
colonoscopies during person time
0.89 (0.39–2.00) 2.05 (1.10–3.82) 3.37 (1.59–7.13)
P for multiplicative interaction 0.41
Total fruit and vegetables intake (g/day)
Dietary supplement use ,179 179–283 283–387 $387
No use a
No. of cases/non-cases 26/51 10/60 15/51 18/51
Person time (months, median) 34.3 45.9 45.3 36.8
HR (95% CI) adjusted for age, sex, and number of
colonoscopies during person time
1.0 0.48 (0.23–1.03) 0.88 (0.44–1.74) 0.78 (0.45–1.35)
Use b
No. of cases/non-cases 16/25 13/34 14/38 14/34
Person time (months, median) 27.2 42.1 40.3 35.9
HR (95% CI) adjusted for age, sex, and number of
colonoscopies during person time
1.25 (0.63–2.52) 0.97 (0.45–2.08) 0.96 (0.45–2.03) 0.66 (0.29–1.50)
P for multiplicative interaction 0.39
a No use of dietary supplements during the last month
b Use of any dietary supplement during the last month
doi:10.1371/journal.pone.0066819.t004
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beneficial role in the prevention of colorectal cancer due to its anti-
angiogenic and anti-inflammatory properties and its regulatory
role in cell proliferation and apoptosis. [33–36] Nevertheless, the
potentially increased risk for developing colorectal adenomas due
to supplements containing fish oil in our study corresponds with
findings in a nested case-control study within the VITamins And
Lifestyle cohort. High intake of n-3 PUFA from diet plus
supplements was associated with a decreased risk of colorectal
cancer among those at low genetic risk (HR = 0.23; 95% CI:
0.07–0.78), while such intake was associated with a substantially
increased risk among those at high genetic risk (HR= 5.79; 95%
CI: 1.79–18.7). Genetic risk was calculated using a genetic risk
score enumerating the number of risk alleles present at 16 single
nucleotide polymorphisms (SNPs) located within known/recently-
identified CRC susceptibility loci (Personal communication,
Elizabeth Kantor). Expansion of our Lynch syndrome cohort
and a longer follow up are essential to further investigate the role
of fish oil supplements and colorectal adenoma risk.
Stratified analyses for MMR carriers with and without a history
of colorectal neoplasms before study entry showed no association
for dietary supplement use and colorectal adenoma risk among
those without a history of colorectal neoplasms, whereas a
borderline statistically significantly increased risk was observed
for MMR carriers with a history of colorectal neoplasms. Due to
the low number of users reflected in the wide confidence intervals
in this study, we are not able to draw firm conclusions considering
differences between these two groups.
Several critical points regarding the study design and dietary
supplement use need to be highlighted. The combined analysis of
all the different kinds of dietary supplements on colorectal
adenoma risk may mask individual effects of each nutrient
supplement. Although this study is the largest prospective study
in MMR gene mutation carriers up until now, the small number of
users of individual dietary supplements in our study narrows the
extent to which we can observe associations.
MMR gene mutation carriers might have increased their dietary
supplement intake based on their health status and risk, [28] and
may therefore have a higher use of dietary supplements compared
to the general Dutch population. However, dietary supplement use
in this Lynch syndrome population was similar (40%) to the
general Dutch population (30–56%); also in our study dietary
supplement users were more often women. [37] Moreover, we
relied on self-reporting which makes misclassification of dietary
supplement use possible. However, according to several studies,
self-reported dietary supplement use is a reliable method to
measure intake of dietary supplements. [38–40] Thus, dietary
supplement use in individuals with Lynch syndrome included in
this study reflects use in the general Dutch population and is a
reliable indicator for the actual intake.
As information on dosage and duration was not assessed, we
could not calculate the total nutrient intake by foods and dietary
supplements together, and were unable to examine changes in
dietary supplement use over time. Our data only allowed us to
examine the associations for dietary supplement use as it was
reported before the events of interest.
Strengths of this study are the inclusion of confirmed MMR
gene mutation carriers in our cohort, and the high participation
rate of 73%. These factors make our findings generalizable to
Lynch syndrome patients in comparable clinical settings. Other
strengths are the prospective cohort design, the relatively long
person time, and the ability to adjust for many potential
confounders.
In conclusion, in this prospective cohort study no associations
between dietary supplement use and colorectal adenoma risk
among individuals with Lynch syndrome were indicated. Further
research is warranted to determine whether or not dietary
supplement use is associated to colorectal adenoma and colorectal
cancer risk in MMR gene mutation carriers.
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